Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2022-03-24 Earnings Release
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: RESULTATS ANNUELS 2021 EN FORTE HAUSSE
Earnings Release Classification · 96% confidence The document is titled "RESULTATS ANNUELS 2021 EN FORTE HAUSSE" (Strong increase in 2021 Annual Results) and presents detailed consolidated financial figures for the fiscal year ended December 31, 2021, including revenue, operating income, and net income. It explicitly mentions that the financial statements for 2021 were approved by the Board on March 24, 2022, and will be submitted to the upcoming shareholders' meeting on May 9th. This content strongly indicates a comprehensive annual financial disclosure. Although it contains elements of an Earnings Release (ER) by summarizing key results and proposing a dividend (DIV), the depth of the financial tables and the discussion of the full fiscal year performance align best with the definition of a comprehensive annual report summary or the core content typically found within an Annual Report (10-K equivalent in structure, though this is likely a French statutory filing). Since the document provides the full year's results and detailed commentary, it is classified as an Annual Report (10-K), which covers full company activity and financial performance for the year, even if it's a press release version rather than the formal SEC filing itself. The mention of the audit being 'in progress' suggests it might precede the final audited 10-K, but the scope is clearly annual results. FY 2021
2022-03-24 French
BIOSYNEX SA: DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 28 FEVRIER 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 28 FEVRIER 2022" (Declaration of the number of shares and voting rights as of February 28, 2022). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) concerning the total number of shares and net voting rights. This content directly relates to the official count of shares and the associated voting power, which is a specific regulatory disclosure related to shareholder rights and capital structure. This aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it declares the total voting rights available as of a specific date, which is crucial information preceding or following a general meeting.
2022-03-15 French
BIOSYNEX SA: SUIVI DES ACTIONS ACHETEES DANS LE CADRE DU PROGRAMME DE RACHAT D'ACTIONS
Transaction in Own Shares Classification · 100% confidence The document is titled "SUIVI DES ACTIONS ACHETEES DANS LE CADRE DU PROGRAMME DE RACHAT D'ACTIONS" (Monitoring of Shares Purchased under the Share Buyback Program) and contains detailed tables showing daily transactions, volumes, and prices for shares bought back by BIOSYNEX between February 10 and February 22, 2022. This explicitly details the company's activity regarding the repurchase of its own shares. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), but a specific report on share repurchases.
2022-03-01 French
BIOSYNEX SA: MULTIPLICATION PAR 2,5 DU CHIFFRE D'AFFAIRES 2021 A 383 M€
Earnings Release Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and provides preliminary financial highlights for the year 2021, including revenue figures (CA) and commentary on business performance and future outlook. It explicitly states that the 2021 figures are unaudited ("chiffres 2021 non audités") and announces the date for the full annual results publication ("Résultats annuels 2021, le 24 mars 2022"). This structure—a press release announcing key financial metrics before the official, audited report—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but the initial announcement of results. FY 2021
2022-01-20 French
BIOSYNEX SA: SIGNATURE AVEC THERADIAG D'UN CONTRAT DE DISTRIBUTION DU TEST PCR AMPLIQUICK SARS-COV-2 DE BIOSYNEX
Regulatory Filings Classification · 95% confidence The document announces a distribution agreement between BIOSYNEX and THERADIAG regarding a specific PCR test. It details the context of BIOSYNEX's increased stake in THERADIAG, the terms of the two-year distribution contract, and future governance considerations (board representation). This type of announcement, detailing a significant business partnership, strategic cooperation, and related corporate actions (like potential board seat nominations), does not fit neatly into standard periodic financial reports (10-K, IR, ER) or specific corporate actions like dividends or share buybacks. It is a material business development announcement. Since it is not a standard regulatory filing like a 10-K or a specific financial report, and it details a significant business transaction/partnership, it is best classified as a general Regulatory Filing (RNS) as a catch-all for material, non-standard announcements, or potentially a Transaction in Own Shares (POS) if the focus was purely on the share acquisition, but the primary news is the distribution contract. Given the nature of the announcement (a new commercial contract and related corporate governance discussion), RNS is the most appropriate general regulatory announcement category when a more specific category like M&A (TAR) is not applicable.
2022-01-13 French
BIOSYNEX SA: DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 31 DECEMBRE 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 31 DECEMBRE 2021" (Declaration of the number of shares and voting rights as of December 31, 2021). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations regarding the publication of the total number of shares and net voting rights. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related statutory disclosures about voting power.
2022-01-04 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.